These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 27940380)

  • 1. Biomimetic biodegradable artificial antigen presenting cells synergize with PD-1 blockade to treat melanoma.
    Kosmides AK; Meyer RA; Hickey JW; Aje K; Cheung KN; Green JJ; Schneck JP
    Biomaterials; 2017 Feb; 118():16-26. PubMed ID: 27940380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biodegradable Cationic Polymer Blends for Fabrication of Enhanced Artificial Antigen Presenting Cells to Treat Melanoma.
    Rhodes KR; Isser A; Hickey JW; Ben-Akiva E; Meyer RA; Kosmides AK; Livingston NK; Tzeng SY; Schneck JP; Green JJ
    ACS Appl Mater Interfaces; 2021 Feb; 13(7):7913-7923. PubMed ID: 33573372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy for Tumor Metastasis by Artificial Antigen-Presenting Cells via Targeted Microenvironment Regulation and T-Cell Activation.
    Lu Y; Li L; Du J; Chen J; Xu X; Yang X; Ding C; Mao C
    ACS Appl Mater Interfaces; 2021 Dec; 13(47):55890-55901. PubMed ID: 34787393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Artificial Antigen-Presenting Cells for Immunotherapies.
    Siefert AL; Fahmy TM; Kim D
    Methods Mol Biol; 2017; 1530():343-353. PubMed ID: 28150213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Artificial antigen-presenting cells plus IL-15 and IL-21 efficiently induce melanoma-specific cytotoxic CD8+ CD28+ T lymphocyte responses.
    Yu X; He J; Mongkhoune S; Peng Y; Xie Y; Su J; Zhou SF; Xie XX; Luo GR; Fang Y; Li X; Li X; Zhou N; Zhao YX; Lu XL
    Asian Pac J Trop Med; 2013 Jun; 6(6):467-72. PubMed ID: 23711708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Artificial Antigen-Presenting Cell Delivering 11 Immune Molecules Expands Tumor Antigen-Specific CTLs in
    Zhang L; Song S; Jin X; Wan X; Shahzad KA; Pei W; Zhao C; Shen C
    Cancer Immunol Res; 2019 Jul; 7(7):1188-1201. PubMed ID: 31113806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PEGylated and CD47-conjugated nanoellipsoidal artificial antigen-presenting cells minimize phagocytosis and augment anti-tumor T-cell responses.
    Song S; Jin X; Zhang L; Zhao C; Ding Y; Ang Q; Khaidav O; Shen C
    Int J Nanomedicine; 2019; 14():2465-2483. PubMed ID: 31040669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biodegradable microparticles loaded with doxorubicin and CpG ODN for in situ immunization against cancer.
    Makkouk A; Joshi VB; Wongrakpanich A; Lemke CD; Gross BP; Salem AK; Weiner GJ
    AAPS J; 2015 Jan; 17(1):184-93. PubMed ID: 25331103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
    Lu L; Xu X; Zhang B; Zhang R; Ji H; Wang X
    J Transl Med; 2014 Feb; 12():36. PubMed ID: 24502656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
    Guo Z; Wang H; Meng F; Li J; Zhang S
    J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Shape matters: Biodegradable anisotropic nanoparticle artificial antigen presenting cells for cancer immunotherapy.
    Ben-Akiva E; Hickey JW; Meyer RA; Isser A; Shannon SR; Livingston NK; Rhodes KR; Kosmides AK; Warren TR; Tzeng SY; Schneck JP; Green JJ
    Acta Biomater; 2023 Apr; 160():187-197. PubMed ID: 36812956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
    Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel system of artificial antigen-presenting cells efficiently stimulates Flu peptide-specific cytotoxic T cells in vitro.
    Han H; Peng JR; Chen PC; Gong L; Qiao SS; Wang WZ; Cui ZQ; Yu X; Wei YH; Leng XS
    Biochem Biophys Res Commun; 2011 Aug; 411(3):530-5. PubMed ID: 21756876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intratumoral injection of IFN-β induces chemokine production in melanoma and augments the therapeutic efficacy of anti-PD-L1 mAb.
    Uehara J; Ohkuri T; Kosaka A; Ishibashi K; Hirata Y; Ohara K; Nagato T; Oikawa K; Aoki N; Harabuchi Y; Ishida-Yamamoto A; Kobayashi H
    Biochem Biophys Res Commun; 2017 Aug; 490(2):521-527. PubMed ID: 28624449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peritumoral administration of DRibbles-pulsed antigen-presenting cells enhances the antitumor efficacy of anti-GITR and anti-PD-1 antibodies via an antigen presenting independent mechanism.
    Patel JM; Cui Z; Wen ZF; Dinh CT; Hu HM
    J Immunother Cancer; 2019 Nov; 7(1):311. PubMed ID: 31747946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythrocyte Membrane-Enveloped Polymeric Nanoparticles as Nanovaccine for Induction of Antitumor Immunity against Melanoma.
    Guo Y; Wang D; Song Q; Wu T; Zhuang X; Bao Y; Kong M; Qi Y; Tan S; Zhang Z
    ACS Nano; 2015 Jul; 9(7):6918-33. PubMed ID: 26153897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
    Li B; VanRoey M; Wang C; Chen TH; Korman A; Jooss K
    Clin Cancer Res; 2009 Mar; 15(5):1623-34. PubMed ID: 19208793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy.
    Shi J; Chen C; Ju R; Wang Q; Li J; Guo L; Ye C; Zhang D
    J Immunother Cancer; 2019 Sep; 7(1):246. PubMed ID: 31511064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanoscale artificial antigen presenting cells for T cell immunotherapy.
    Perica K; De León Medero A; Durai M; Chiu YL; Bieler JG; Sibener L; Niemöller M; Assenmacher M; Richter A; Edidin M; Oelke M; Schneck J
    Nanomedicine; 2014 Jan; 10(1):119-29. PubMed ID: 23891987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.
    Chauvin JM; Pagliano O; Fourcade J; Sun Z; Wang H; Sander C; Kirkwood JM; Chen TH; Maurer M; Korman AJ; Zarour HM
    J Clin Invest; 2015 May; 125(5):2046-58. PubMed ID: 25866972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.